In 2012, Biotech IPOs Continue Their Inside Story
This article was originally published in Start Up
Among the new realities for life science VCs, from structured acquisitions to no-go therapeutic areas, it looks like we can add insider participation in IPOs to the list. It's been nearly a year since a life-science company went public in the US without its private investors pitching in.
You may also be interested in...
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.